

UNIVERSITY OF HELSINKI
Institute for Molecular Medicine Finland FIMM
Technology Centre

**CONTRACT FOR A RESEARCH PROJECT
“SOPIMUS TUTKIMUSHANKKEESTA”**

Parties:

Technology Centre, Institute for Molecular Medicine Finland FIMM, University of Helsinki,
Finland (hereafter TC)

Contact person:

Pekka Ellonen
Technology Centre
Institute for Molecular Medicine Finland FIMM
University of Helsinki
PO Box 20 (Tukholmankatu 8)
00014 University of Helsinki
pekka.ellonen @helsinki.fi
tel. +358 50 415 4481

And

Xxx (hereafter Research Group)

Contact person:

Hereinafter together “Parties” and individually “Party”

Is the project funded by the EU? **YES / NO**

Are the project samples biobank samples? **YES/NO**

Billing address:

xx

1. The project

The title of the project is ”**xxx**”. The principal investigator of the project is **xxx**, and the other investigators are **xxx**. The scientific aim of the project is to **xxxx**. The study material includes **xxx** samples. (**further description of the material, if needed**)

2. Responsibilities of the Research Group

Research Group assumes all responsibility for patient contacts, phenotyping of patients, collection of samples and extraction of DNA.

Research Group will provide TC with DNA samples to be processed, a file with sample identifiers, pedigree information (where applicable), and general sample information, such as concentrations. General patient information or affection status information is supplied only if needed for statistical analysis. No information that can be used to identify the sample donors should be supplied.

3. Responsibilities of the TC

TC has established a laboratory suitable for medium to high throughput NGS analysis, and an IT infrastructure for handling of sample and result information. TC will perform NGS library preparations, library enrichments and subsequent massively parallel sequencing using workflows established in TC. Massively parallel sequencing will be performed on Illumina's platforms (MiSeq, HiSeq or NovaSeq series).

TC will perform routine quality control steps to ensure high quality of the results, and analyse the data of each sample using in-house built pipelines.

4. The form of collaboration and publication policy

The project is a service project. Accordingly, TC will be acknowledged in any publication(s) including data obtained by TC as follows: "Sequencing was performed by the Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki." TC should be informed of any future publications where the work performed at TC has a contribution.

Or:

The project is a scientific collaboration project. TC takes active part in planning of the project, or analysis of the results. The TC scientists shall also participate in publications based on the said work, as agreed with the principal investigator of the project. TC should be informed of any future publications where the work performed at TC has a contribution.

5. Sharing of costs

Research group shall cover the costs of the project according to the current FIMM Technology Centre price list. The costs are based on current prices of consumables involved in the study, especially Illumina sequencing reagent pricing. The total cost per sample is a combination of following services (external academic prices, VAT 0%):

please add – can be replaced by iLAB content

In case of any additional work the price and other conditions shall be covered by a new agreement (written or verbal).

6. Public information and confidentiality

The project name and the name and address of the principal investigator may be published at the TC / FIMM web site and may be mentioned at public talks by TC personnel. All other information concerning the present project will be kept confidential. All contacts concerning the project or questions concerning any details of the project will be directly forwarded to the principal investigator. The results and sample information shall be stored at the TC database for ten (10) months also after the completion of the project. After this period TC is no longer responsible for storing the results and sample information nor destroying it. (is this even OK by GDPR?)

TC will deliver the final data only to the contact persons.

7. Data usage and protection of study subjects

No individual result data directly linked to the study subjects may be given to any third party, including subjects participating in the project, unless approved by the Ethical Review board permit. The data may not be used for diagnostic purposes unless otherwise agreed by both parties.

Sequencing analysis at TC is intended for research use only. TC does not provide clinical service unless otherwise agreed by both parties nor accepts any responsibility for individual data delivered against this contract to third parties. While TC believes that the result data are of high standard quality, any interpretations based on these results are the responsibility of the research group and no warranty of the results is given by TC.

The Research Group represents and warrants that the study has been approved by the appropriate Ethical Review board(s) and the investigators approve to the best of their knowledge that the study has been executed according to rules, regulations and best practices applicable to such biomedical research.

This project follows European GDPR regulations. A Data Processing Agreement is attached to this Contract.

8. Miscellaneous

This Agreement is governed by the laws of Finland. Any dispute that cannot be agreed through negotiations shall be settled in the District Court of Helsinki.

All claims against TC shall be raised within one (1) year from the expiry or termination of this Agreement.

The liability of TC is limited to the amount paid to TC by the Research Group. A Party is not responsible for any indirect or consequential damages. The limitations of liability do not apply if the damages were caused by a wilful act or gross negligence.

Signed by:

Date

Principal investigator (xx)

Janna Saarela
Director of TC